drugset / Trial / NCT00925535

Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)

NCT00925535

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

Approximately 1/3 of persons living with HIV infection are co-infected with tuberculosis (TB). Rifabutin, used in the treatment of TB, is an inducer of drug metabolism thus may decrease concentrations of lersivirine if co-administered. Lersivirine is a modest inducer of drug metabolism, thus lersivirine may decrease concentrations of rifabutin as well.

Timeline

Start
2010-05
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lersivirine Small molecule 1000 mg
Subject Rifabutin Small molecule 300 mg

Indications

No indication recorded.